The relationship between medical technology (MedTech) and defence technology has historically been characterised by an ad hoc, one-directional flow of innovation, often described as a "spin-out" effect where military research unexpectedly finds civilian applications. However, a contemporary analysis reveals a more complex, mutually beneficial, and increasingly institutionalized symbiosis. This interdependence is no longer a matter of serendipitous discovery but a deliberate,

The landscape of business education in Europe is undergoing a fundamental transformation, with HealthTech emerging as a critical nexus of innovation, capital, and leadership. This analysis posits that the traditional metrics of institutional prestige, while important, no longer provide a complete picture for prospective students and industry partners. A more granular, and ultimately more valuable, evaluation necessitates an in-depth examination of a school's specific HealthTe

The landscape of obesity and cardiometabolic disease management is on the cusp of a profound transformation, driven by the emergence of a new generation of oral therapies. For years, the remarkable efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss and glycemic control has been inextricably linked to injectable formulations, creating a market dominated by medications like semaglutide (Wegovy) and tirzepatide (Zepbound). However, the imminent approva

This report provides a detailed analysis of Nelson Advisors, a highly specialised mergers and acquisitions (M&A), partnerships and investment advisory firm. The firm is exclusively dedicated to the dynamic European medical technology (MedTech) sector, with an extended reach into the UK and North America. The analysis reveals that the firm's primary competitive advantage is rooted in its unique "Founders for Founders" approach, which is underpinned by the direct entrepreneuria

The global gut health market is in the midst of a profound transformation, evolving from a niche category focused on basic digestive relief into a mainstream, data-driven wellness sector. Projected to grow from $38.8 Billion in 2021 to $90.2 Billion by 2031 with a compound annual growth rate (CAGR) of 8.8%, this market is poised for robust expansion. This growth is not merely a quantitative increase but a qualitative shift, driven by a foundational change in consumer mindset

Ambient Voice Technology (AVT), once considered a speculative innovation, is rapidly evolving into a strategic necessity for healthcare organizations. Fuelled by an urgent need to combat clinician burnout, address rising administrative workloads, and enhance operational efficiency, AVT is poised to fundamentally reshape the clinical workflow. The market is transitioning from an experimental phase to a mature, regulated ecosystem where this technology is no longer a luxury but

Nelson Advisors Partner Lloyd Price invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 . The Investor Forum at the Global Health Exhibition 2025 is a premier platform for investors, innovators, and healthcare leaders to explore transformative investment opportunities in Saudi Arabia’s rapidly evolving healthcare landscape.

Nelson Advisors partner Lloyd Price interviewed by Digital Health for their 'NHS App to unleash its full potential' story. Lloyd Price, partner at Nelson Advisors and health tech founder, said that the NHS App needs a “killer feature” to increase its usage and “unlock further organic and viral growth”. He added that the main functions of the NHS App to book GP appointments and order repeat prescriptions can be done through other apps such as Patient Access from EMIS, MyGP fr

The European HealthTech market in 2026 is at a pivotal juncture, moving from a period of early-stage experimentation to a more grounded, results-oriented reality. Success for all stakeholders—from innovative founders to strategic buyers—is predicated on navigating a complex and converging landscape defined by regulatory maturation, a selective funding environment, and an accelerated trend of market consolidation. The core thesis of this report is that a strategic shift is req

The global MedTech sector is entering a new era of mergers and acquisitions (M&A) characterised by a pronounced shift from broad portfolio expansion to highly selective, technology-driven acquisitions. While the broader healthcare M&A landscape experienced a decline in deal volume and value in 2024, the MedTech sub-sector demonstrated remarkable resilience. This report highlights that a period of market resurgence is underway, driven by a strategic focus on a smaller number o

Nelson Advisors Partner Lloyd Price has been invited to Judge the 'HealthInvestor Power List 2025 Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care.

The integration of artificial intelligence (AI) into healthcare is not a question of if, but how. This report asserts that for AI to be implemented ethically and effectively, the nursing profession must be at the forefront of its development. Nurses are not merely the end-users of these technologies; they are the indispensable link between raw patient data and human-centered care. By shifting from a traditional technology-first approach to a collaborative, human-in-the-lo

The year 2026 is poised to be a pivotal year for the integration of artificial intelligence into healthcare, marked by the maturation of a new class of specialised systems known as Personal Health Large Language Models (PH-LLMs). These models represent a fundamental shift beyond general-purpose AI, moving from broad-based utility to domain-specific reliability. They are positioned to revolutionise the HealthTech landscape by acting as intelligent, reasoning engines that enhan

Nelson Advisors Partner Lloyd Price will lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia. #GHE25 The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare.

Venture debt has emerged as a critical and purpose-built financial instrument within the dynamic and capital-intensive health technology (healthtech) sector. This report provides an analysis of its strategic role, delineating its distinct strengths, inherent weaknesses, current opportunities and future trajectory. Venture debt is defined as a specialised loan for high-growth, venture-backed startups, uniquely underwritten based on a company's ability to raise future equity ra